Figure 1 | British Journal of Cancer

Figure 1

From: Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma

Figure 1

Trastuzumab- and Cetuximab-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) of peripheral blood mononuclear cells (PBMCs) from patients and healthy donors. (A) Cetuximab-mediated ADCC of PBMCs from patients (oesophageal squamous cell carcinoma (ESCC), n=12) and healthy donors (healthy, n=10) was analysed against high EGFR-expressing KYSE30 and low EGFR-expressing KYSE110 cells in the presence of Cetuximab or control mAbs at the indicated effector : target ratios (10 : 1, 20 : 1, and 40 : 1). *P<0.05. (B) Trastuzumab-mediated ADCC of PBMCs from patients (ESCC, n=8) and healthy donors (healthy, n=6) was analysed against high HER2-expressing TE4 and low HER2-expressing KYSE50 cells in the presence of Trastuzumab or control mAbs at the indicated effector : target ratios (10 : 1, 20 : 1, and 40 : 1). *P<0.05. The expression of EGFR or HER2 on target tumour cells was shown as mean fluorescence intensity (MFI) analysed by flow cytometry.

Back to article page